# Bordetella bronchiseptica: Microbiology, Pathogenesis, Diagnostics, and Control in Veterinary Medicine ## Key Takeaways - *Bordetella bronchiseptica* is a Gram-negative coccobacillus that causes significant respiratory disease in multiple mammalian species, including dogs (CIRDC), pigs (atrophic rhinitis), and cats, often acting as a primary or secondary pathogen. - Virulence is mediated by adhesins (filamentous hemagglutinin, pertactin, fimbriae), toxins (dermonecrotic toxin, adenylate cyclase toxin), and a type III secretion system, with colonization facilitated by novel factors like b-Cool. - Diagnosis relies heavily on molecular methods such as real-time PCR for rapid and sensitive detection from nasal swabs or bronchoalveolar lavage fluid, though bacterial culture and serology (ELISA) remain valuable adjuncts. - Vaccination strategies include live attenuated oral/intranasal vaccines for dogs and inactivated injectable vaccines for cats, aiming to induce rapid mucosal immunity and reduce clinical signs and shedding. - Antimicrobial resistance to macrolides, tetracyclines, and sulfonamides is a growing concern in *B. bronchiseptica* isolates, necessitating susceptibility testing or informed empirical choices, with doxycycline often being a first-line treatment. - *B. bronchiseptica* possesses zoonotic potential, particularly in immunocompromised humans, with genomic studies revealing evolutionary pathways that facilitate host switching from animal reservoirs. --- ## Introduction and Taxonomic Classification *Bordetella bronchiseptica* is a Gram-negative, aerobic, coccobacillus belonging to the genus *Bordetella* within the family Alcaligenaceae [1, 2]. The organism is a primary or secondary respiratory pathogen of many mammalian hosts, including dogs, cats, pigs, rodents, lagomorphs, and non‑human primates [3, 4, 5, 6]. Phylogenetically, *B. bronchiseptica* clusters closely with *Bordetella pertussis* and *Bordetella parapertussis*, but it retains a broader host tropism and a more versatile genomic repertoire [4, 7]. The species is a common etiological agent of canine infectious respiratory disease complex (CIRDC), often referred to as kennel cough [Bordetella bronchiseptica in Dogs and Cats: Kennel Cough Pathogenesis, Diagnosis, and Control](/knowledge/bacteria/pet-bacteria/bordetella-bronchiseptica-kennel-cough-dogs-cats-diagnosis). In swine, it is a key contributor to progressive and non‑progressive atrophic rhinitis [Bordetella bronchiseptica and Atrophic Rhinitis in Pigs: Turbinate Atrophy and Diagnosis](/knowledge/bacteria/livestock-bacteria/bordetella-bronchiseptica-atrophic-rhinitis-pigs). The bacterium also causes upper respiratory infections in cats, often in concert with feline herpesvirus‑1 and calicivirus [Feline Upper Respiratory Infections (Feline Herpesvirus, Calicivirus, and Bordetella): Etiology, Clinical Signs, Zoonotic Potential, and Therapeutics](/knowledge/bacteria/pet-bacteria/feline-upper-respiratory-infections-herpesvirus-calicivirus-bordetella). ## Microbiology and Virulence Determinants *B. bronchiseptica* expresses a suite of virulence factors that enable colonization, immune evasion, and tissue damage. Key adhesins include filamentous hemagglutinin, pertactin, and fimbriae; the latter are encoded by the *fim* locus, which exhibits substantial diversity among isolates [8]. The *fimX* locus, in particular, shows variable allelic content that may influence host specificity [8]. A recently described colonization glycan, termed b‑Cool (Bordetellae colonization oligosaccharide), is critical for nasal colonization and resistance to mucociliary clearance [2]. The bacterium produces several toxins. Dermonecrotic toxin (DNT) is a heat‑labile protein that causes turbinate atrophy in pigs and contributes to nasal pathology in other species [9]. Adenylate cyclase toxin (CyaA) is a bifunctional enzyme that elevates intracellular cyclic AMP, impairing phagocyte function; its acylation and secretion patterns differ among *Bordetella* species and may correlate with virulence [10]. The type III secretion system (T3SS) injects effector proteins into host cells; the tip filament of the injectisome undergoes dynamic assembly regulated by environmental cues [11]. Cyclic di‑GMP (c‑di‑GMP) signaling modulates biofilm formation and motility, with architectural and regulatory functions that are conserved across classical *Bordetella* species [1]. Biofilm regulation is further influenced by albumin and calcium, which act as environmental signals [12]. ## Clinical Syndromes and Host Range ### Dogs In dogs, *B. bronchiseptica* is a predominant bacterial cause of CIRDC. Clinical features include paroxysmal coughing, mucopurulent nasal discharge, and, in severe cases, bronchopneumonia [13]. Risk factors for lower respiratory tract involvement include concurrent viral infection, immunosuppression, and shelter housing [13]. Acute bronchopneumonia with bacteremia, although rare, has been documented in immunocompromised dogs [14]. Bacteremia is more commonly reported in human cases, but analogous presentations occur in dogs with severe mucosal damage. ### Cats Feline infection is often subclinical or manifests as mild conjunctivitis and sneezing. In multi‑cat environments, *B. bronchiseptica* can cause overt respiratory disease, particularly in kittens [15]. The organism is frequently detected in cats co‑infected with feline herpesvirus‑1 or calicivirus [Feline Upper Respiratory Infections: Etiology, Transmission, Clinical Management, and Zoonotic Potential](/knowledge/bacteria/pet-bacteria/feline-respiratory-infections-causes-treatment-zoonosis). ### Pigs *B. bronchiseptica* is a primary agent of non‑progressive atrophic rhinitis and predisposes pigs to colonization by toxigenic *Pasteurella multocida*, which causes progressive atrophic rhinitis [16, 17]. A vertical transmission model has been developed, demonstrating that sows can transmit the bacterium to piglets, contributing to early‑life colonization [16]. ### Wildlife Eastern gray squirrels (*Sciurus carolinensis*) harbor *B. bronchiseptica* at variable prevalence, with no clear association with clinical disease [3]. In koalas (*Phascolarctos cinereus*), the bacterium is detected in both healthy and diseased animals, often alongside *Chlamydia* spp. and gammaherpesviruses [5]. Non‑human primates (e.g., macaques) carry genetically diverse *B. bronchiseptica* strains, some of which are closely related to human isolates [6]. ### Zoonotic Potential *B. bronchiseptica* can infect immunocompromised humans, causing pneumonia, chronic cough, and empyema [14, 18, 19, 20]. Genomic analyses of swine‑human interface isolates reveal evolutionary pathways that facilitate host switching, emphasizing the [zoonotic risk](/knowledge/parasites/pet-parasites/zoonotic-risk-humans-get-parasites-from-pets) posed by livestock reservoirs [4]. However, human‑to‑human transmission is considered uncommon. ## Diagnostic Approaches Accurate diagnosis relies on a combination of culture, molecular methods, and serology. The table below summarizes the principal diagnostic techniques. | Method | Sample Type | Sensitivity / Specificity | Key Reference(s) | |----|-------|--------------|---------| | Bacterial culture | Nasal swab, bronchoalveolar lavage (BAL) fluid | Moderate sensitivity; gold standard for isolation | [21] | | Real‑time PCR | Nasal swab, BAL fluid, blood | High sensitivity and specificity; detects low‑level shedding | [21, 22] | | Multiplex PCR / LAMP | Respiratory swabs | High throughput; simultaneous detection of multiple *Bordetella* species | [23] | | Serology (ELISA) | Serum | Correlates with infection but not always with active disease; serum amyloid A may aid interpretation | [24] | | Automated impedance analyzers | Blood culture | Used for bacteremia detection | [14] | Molecular diagnostics are increasingly preferred because of speed and sensitivity. Real‑time PCR using the IS481 insertion sequence (shared with *B. pertussis*) can cause confusion; species‑specific targets (e.g., *recA*, *pixP*) improve discrimination [23, 25]. A combined PCR and LAMP assay targeting multiple *Bordetella* species has been developed for use in respiratory panels [23]. Point‑of‑care molecular platforms for feline upper respiratory pathogens, including *B. bronchiseptica*, are available for veterinary clinics [Point‑of‑Care Molecular Diagnostics for Feline Upper Respiratory Pathogens: FHV‑1, FCV, and Bordetella](/knowledge/diagnostics/emerging-tech/point-of-care-molecular-diagnostics-feline-upper-respiratory-fhv1-fcv-bordetella). Serological detection by ELISA has been correlated with infection in dogs, and serum amyloid A levels may serve as an adjunct marker for active disease [24]. Multiplex bead‑based assays enable simultaneous detection of antibodies against multiple feline respiratory pathogens [Development of a Multiplex Bead‑Based Serological Assay for Detection of Antibodies against Feline Respiratory Pathogens (FHV‑1, FCV, and Bordetella bronchiseptica)](/knowledge/diagnostics/serology-immunology/multiplex-bead-based-serological-assay-feline-respiratory-pathogens). ### Diagnostic Decision Tree The following Mermaid diagram illustrates a diagnostic workflow for a dog [or cat](/knowledge/veterinary-medicine/preventive-care/or-cat-logical-health) presenting with respiratory signs. ```mermaid flowchart TD A["Respiratory signs: cough, nasal discharge, sneezing"] --> B{"Clinical severity?"} B -->|"Mild"| C["Non‑invasive swab: nasal or oropharyngeal"] B -->|"Severe or chronic"| D["BAL or transtracheal wash"] C --> E["Real‑time PCR for B. bronchiseptica + viral panel"] D --> E E -->|"Positive for B. bronchiseptica"| F{"Co‑pathogen detected?"} E -->|"Negative"| G["Consider culture, serology, or alternative diagnosis"] F -->|"Yes"| H["Treat primary pathogen + manage B. bronchiseptica"] F -->|"No"| I["Antimicrobial therapy guided by susceptibility or business intelligence tools"] I --> J["Monitor clinical response"] J -->|"No improvement"| K["Repeat PCR ± culture from BAL; consider resistance testing"] ``` ## Vaccination Strategies Multiple vaccine formulations are available for dogs and cats, including live attenuated oral, intranasal, and injectable inactivated products. The table below summarizes key vaccine studies. | Vaccine Type | Route | Target Species | Duration of Immunity | Key Findings | References | |-------|----|--------|-----------|-------|------| | Live attenuated (Vanguard B Oral) | Oral | Dog | At least 7 days after a single dose; 1 year with booster | Induces protective immunity against challenge; reduces shedding | [26, 27] | | Inactivated | Injectable | Cat | At least 1 year | Safe and efficacious; reduces clinical signs after challenge | [15] | | BcfA‑containing intranasal | Intranasal | Mouse (model) | Not defined in target species | Induces Th17 immunity and reduces nasal colonization | [28] | | Vitamin E adjuvanted injectable | Injectable | Dog | Not defined | Safe and efficacious; serological response comparable to commercial vaccines | [29] | | Outer membrane protein subunit | Injectable | Mouse (model) | Not defined | Protects against challenge; induces humoral and cellular responses | [30] | | Trivalent nanocage | Injectable | Mouse (model) | Cross‑species protection | Programmable; durable protection against heterologous strains | [31] | Oral and intranasal vaccines are preferred in dogs for rapid mucosal immunity; injectable formulations are used in cats and as alternatives in dogs [15, 26, 29]. A novel nanocage‑based vaccine demonstrates cross‑species protection, suggesting potential for future broad‑spectrum applications [31]. ## Antimicrobial Resistance and Treatment Acquired antimicrobial resistance genes in *B. bronchiseptica* have been characterized globally. Genomic analyses reveal that resistance to macrolides, tetracyclines, and sulfonamides is common in porcine and canine isolates, while fluoroquinolone resistance remains less frequent [7]. Business intelligence tools that integrate local surveillance data can guide empirical antimicrobial choices [32]. Doxycycline is often the first‑line agent, but susceptibility testing is advised when feasible. ## Phage Therapy Bacteriophages represent a promising alternative to antibiotics for treating *B. bronchiseptica* infections. A phage with dual host specificity for canine and porcine isolates has been isolated and shown to disrupt biofilms [33]. A broad‑spectrum lytic phage capable of lysing multiple *Bordetella* species has also been characterized, raising the possibility of pan‑Bordetella phage therapy [34]. Phage therapy is not yet approved for veterinary use but is under active investigation. ## Pathogen Evolution and Genomics Comparative genomics reveals substantial diversity among *B. bronchiseptica* isolates from primates, with distinct lineages correlating with geographic origin and host species [6]. The fimX locus is hypervariable, likely driven by host immune selection [8]. Genetic events at the swine‑human interface have been traced, showing that zoonotic strains evolve by acquisition of pertussis‑toxin‑like loci and loss of host‑restriction factors [4]. c‑di‑GMP signaling networks show nuanced differences across classical *Bordetella* species, affecting virulence gene expression [1]. ## Frequently Asked Questions ### What is Bordetella bronchiseptica? *Bordetella bronchiseptica* is a Gram‑negative coccobacillus that causes respiratory infections in many mammals, including dogs, cats, pigs, rodents, and non‑human primates [1, 2]. It is a primary component of the canine infectious respiratory disease complex and contributes to atrophic rhinitis in pigs. ### How is Bordetella bronchiseptica transmitted? Transmission occurs via aerosolized respiratory droplets, direct contact with contaminated fomites, and, in swine, vertically from sow to piglet [16]. Crowded housing conditions, such as shelters and kennels, facilitate rapid spread. ### What are the clinical signs in dogs? Dogs typically develop a harsh, paroxysmal cough, nasal discharge, and occasional fever; in severe cases, bronchopneumonia and bacteremia can occur [13, 14]. ### What are the clinical signs in cats? Cats often exhibit mild sneezing, conjunctivitis, and serous nasal discharge, but kittens and immunocompromised adults may develop pneumonia [15]. ### How is Bordetella bronchiseptica diagnosed? Diagnosis is confirmed by real‑time PCR performed on nasal swabs or bronchoalveolar lavage fluid; culture and serology are adjunct methods [21, 23, 24]. Multiplex panels can distinguish *B. bronchiseptica* from other *Bordetella* species. ### What vaccines are available? Oral live attenuated, intranasal, and injectable inactivated vaccines are licensed for dogs and cats [15, 26, 29]. Experimental subunit, nanocage, and Th17‑inducing vaccines have shown promise in murine models [28, 30, 31]. ### Is Bordetella bronchiseptica zoonotic? Yes, immunocompromised humans can acquire infection from animals, particularly through contact with pigs or dogs [4, 14, 18, 19, 20]. Person‑to‑person spread is rare. ### How is infection treated? Doxycycline is a common first‑line antimicrobial, but susceptibility testing is recommended due to increasing antimicrobial resistance [7, 32]. Phage therapy is being explored as an alternative [33, 34]. ## References [1] Vondrova D, Mugni SL, Blumenstein J, et al. Architecture and regulatory functions of c‑di‑GMP signaling in classical Bordetella species. *FEMS Microbiol Rev*. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41452322/ [2] Su Y, Callender M, Woolsey D, et al. Bordetellae colonization oligosaccharide (b‑Cool), a glycan crucial for nasal colonization. *Sci Adv*. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40901963/ [3] Laird G, Calinger‑Yoak A, Zhang Q. Survey of Bordetella bronchiseptica in Eastern Gray Squirrels (Sciurus carolinensis). *Ecohealth*. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41989687/ [4] Liu J, Zheng X, Jia C, et al. Zoonotic Bordetella bronchiseptica infection at the swine‑human interface: unveiling the evolutionary path from an animal to a human pathogen. *Emerg Microbes Infect*. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41729089/ [5] Pollak NM, Phillips S, Kasimov V, et al. Chlamydia spp., Bordetella bronchiseptica, and Phascolarctid Gammaherpesvirus 1 and 2 Infections in Koalas (Phascolarctos cinereus) in South East Queensland, Australia: Detection in Healthy Individuals and Those with Signs of Respiratory or Other Disease. *J Wildl Dis*. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41638597/ [6] Nicholson TL, Shore SM, Wang Y, et al. Genetic diversity of Bordetella bronchiseptica isolates obtained from primates. *Front Microbiol*. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40641881/ [7] Tang B, Hu X, Song Y, et al. Acquired antimicrobial resistance genes in Bordetella Species: a global genomic analysis. *J Antimicrob Chemother*. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41324307/ [8] Nicholson TL, Shore SM. Comparative analysis of the diversity within the B. bronchiseptica fimX locus. *PLoS One*. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41770752/ [9] Schaaf D, Dresen M, Weldearegay YB, et al. Mono‑ and co‑infections of primary porcine respiratory cells with Bordetella bronchiseptica and Streptococcus suis are not affected by the dermonecrotic toxin. *Infect Immun*. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41817187/ [10] Wolber AR, McKay LS, Mote KB, et al. Nuanced differences in adenylate cyclase toxin production, acylation, and secretion may contribute to the evolution of virulence in Bordetella species. *mBio*. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40387377/ [11] Malcova I, Zmuda M, Valecka J, et al. Assembly and dynamic regulation of the tip filament of the Bordetella type III secretion system injectisome. *mBio*. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40980893/ [12] Mugni SL, Ambrosis N, O Toole GA, et al. Interplay of virulence factors and signaling molecules: albumin and calcium‑mediated biofilm regulation in Bordetella bronchiseptica. *J Bacteriol*. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40135913/ [13] Marshall GR, Makielski KM, Rendahl AK, et al. Clinical features, risk factors, and outcomes of Bordetella bronchiseptica respiratory infections in dogs diagnosed at a tertiary care institution. *J Vet Intern Med*. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42059462/ [14] Takahashi Y, Isshiki R, Kimoto K, et al. Acute bronchopneumonia with Bordetella bronchiseptica bacteremia in an immunocompromised patient with bronchiectasis: A case report and review of the literature. *J Infect Chemother*. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41903648/ [15] Li Y, Dong X, Yang A, et al. Development and efficacy evaluation of an inactivated Bordetella bronchiseptica vaccine in cats. *Vaccine*. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42217448/ [16] Hau SJ, Buckley AC, Arruda B, et al. Development of vertical transmission model for Bordetella bronchiseptica in pigs. *Vet Microbiol*. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41740208/ [17] Lichterfeld H, Trittmacher S, Gerdes K, et al. Correction: Lichterfeld et al. Porcine Nose Atrophy Assessed by Automatic Imaging and Detection of Bordetella bronchiseptica and Other Respiratory Pathogens in Lung and Nose. Animals 2024, 14, 3113. *Animals (Basel)*. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40805115/ [18] Banerjee D, Ayaz E, Hudson A, et al. Chronic Productive Cough in an Immunosuppressed Patient due to Biologics: A Rare Case of Bordetella bronchiseptica Pulmonary Infection. *Respirol Case Rep*. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41503239/ [19] Saleem Siddiqui A. Bordetella bronchiseptica Pneumonia in an Immunocompetent Young Man. *Arch Bronconeumol*. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40783308/ [20] Wray S, Tabliago NRA, Lueking R. B. Bronchiseptica empyema necessitans, a case report. *BMC Pulm Med*. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40346537/ [21] Atencia S, Mateu N, Rodríguez‑Cobos A, et al. Real‑time PCR versus culture of bronchoalveolar lavage fluid for detecting Bordetella bronchiseptica in dogs with persistent lower respiratory signs: a retrospective study of 23 cases. *Vet Res Commun*. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40663178/ [22] Abbasi Bahonar A, Hadian M, Ownagh A, et al. Genomic detection and phylogenetic analysis of Bordetella bronchiseptica in dogs blood samples by PCR method in West Azerbaijan Province, Iran. *Braz J Microbiol*. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41364275/ [23] Koryukov MA, Oscorbin IP, Gordukova MA, et al. Novel multitarget LAMP and PCR assays for the detection of Bordetella species. *Methods*. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40216281/ [24] Akar K, Sanioğlu Gölen G, Ekin İH. Investigation of the Correlation Between ELISA and Serum Amyloid A in the Diagnosis of Bordetella bronchiseptica in Dogs. *Vet Med Sci*. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40214008/ [25] Zarbock CM, Evbuomwan EM, Shenep M, et al. Molecular methods to diagnose pertussis: a case of confusion with Bordetella bronchiseptica. *ASM Case Rep*. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41244292/ [26] Wappel S, Velineni S, King V, et al. Oral administration of a live‑attenuated Bordetella bronchiseptica vaccine (Vanguard B Oral) induces protective immunity against challenge 7 days after vaccination in dogs. *Am J Vet Res*. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42379217/ [27] Wiechert‑Brown SA, Classe HM, Dant JC, et al. One year duration of immunity of a combination Bordetella bronchiseptica, canine parainfluenza oral vaccine in dogs. *Front Vet Sci*. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41164231/ [28] Aubrey AR, Patel KK, Hall JM, et al. A BcfA‑containing intranasal vaccine generated T(H)17 immunity and reduced B. bronchiseptica colonization and disease in mice. *NPJ Vaccines*. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42103775/ [29] Bruton B, Wouters PAWM, Tarpey I, et al. A Novel Vitamin E Adjuvanted Injectable Bordetella bronchiseptica Vaccine Is Safe and Efficacious in Dogs. *Vaccines (Basel)*. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42042820/ [30] Jang JY, Park BJ, Song H, et al. Safety and efficacy of a Bordetella bronchiseptica outer membrane proteins (OMPs) subunit vaccine in a murine model. *J Vet Sci*. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40461428/ [31] He W, Wang L, Zhang X, et al. Programmable trivalent nanocage vaccine confers durable cross‑species protection against Bordetella bronchiseptica infection. *J Nanobiotechnology*. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41736107/ [32] Rodríguez‑Villodres Á, Hoffmann‑Álvarez MV, Camacho‑Martínez P, et al. Usefulness of business intelligence to guide antimicrobial treatment decision in infections by infrequent microorganism such as Bordetella bronchiseptica. *Rev Esp Quimioter*. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40080405/ [33] Li C, Tan L, Ma Y, et al. A bacteriophage with dual host specificity for canine and porcine Bordetella bronchiseptica: Characterization and biofilm disruption potential. *Virology*. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41108833/ [34] Huang X, Hou Y, Zhao M, et al. Identification of a broad‑spectrum lytic Bordetella phage and assessments of its potential for combating Bordetella infections. *Virology*. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40306109/ ## Related Clinical & Scientific Guides * [Duck Diseases: A Comprehensive Overview for Veterinary Practitioners](/knowledge/bacteria/avian-bacteria/duck-diseases-comprehensive-overview-veterinary) * [Salmonella Dublin in Cattle: Emerging Pathogen, Diagnostic Challenges, and Public Health Impact](/knowledge/bacteria/livestock-bacteria/salmonella-dublin-cattle-emerging-pathogen-diagnostic-public-health) * [Mycoplasma Infections in Poultry: Vaccination Strategies and Control Programs](/knowledge/bacteria/avian-bacteria/mycoplasma-infections-in-poultry-vaccination-strategies-and-control-programs)